Cytokinetics Inc vs MPLX LP — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while MPLX LP trades at $59.9 (market cap $60.12B). The key difference: MPLX LP is far larger — about 5.7× Cytokinetics Inc's market cap, and MPLX LP pays a 7.26% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MPLX | |
|---|---|---|
Market Cap | $10.63B | $60.12B |
Sector | Technology | Technology |
52-Week High | $87.26 | $60.51 |
52-Week Low | $34.31 | $47.80 |
Enterprise Value | $10.74B | $85.22B |
Dividend Yield | — | 7.26% |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
MPLX trades at $59.94, up 2.11% today, with a bullish technical signal from moving averages and a consensus analyst price target of $61.50. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though recent quarterly earnings have missed expectations. A recent $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) supports growth initiatives, while a 7.3% dividend yield attracts income investors.
Outlook remains positive given fee-based revenue stability and growth projects, but risks include execution challenges from higher capital spending and leverage. Analyst sentiment is strongly bullish with no sell ratings, though investors should monitor earnings consistency and debt levels amid volatile energy markets.
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →